Platinum chemotherapy (cisplatin or carboplatin)

DRUG2 trials

Sponsors

Hoffmann-La Roche, TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Conditions

Advanced Lung CarcinomaCRC (Colorectal Cancer)KRAS G12AKRAS G12CKRAS G12DKRAS G12SKRAS G12VMetastatic Colorectal Cancer (CRC)

Phase 1

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

RecruitingNCT06917079

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)Advanced Lung Carcinoma, CRC (Colorectal Cancer), KRAS G12A +11

Start: 2025-03-31End: 2029-09-01Target: 387Updated: 2026-03-23

Phase 3

A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

CompletedNCT00883779

Hoffmann-La RocheNon-Squamous Non-Small Cell Lung Cancer

Start: 2009-04-30End: 2014-12-31Updated: 2015-12-14

Related Papers

Abstract 7104: BBO-11818: An orally bioavailable, highly potent and selective non-covalent pan-KRAS(ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models

Cancer Research2026-04-03

Data from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants

2026-04-01

Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants.

2026-03-06

Abstract C082: BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction inhibits tumor growth alone and in combination with KRAS inhibitors in KRAS mutant models without inducing hyperglycemia

Molecular Cancer Therapeutics2025-10-22

Abstract A063: BBO-11818: an orally bioavailable, highly potent and selective non-covalent pan-KRAS(ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models

Molecular Cancer Therapeutics2025-10-22

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

2013-06-17244 citations